Where will tomorrow’s workforce come from? PART 4: Who are tomorrow’s cell and gene therapy workers?

Published: 14 June 2022
Qasim Rafiq, Tiffany Hood, Lihi Livne, Sebastian Rudden

Welcome to a four-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment: “Where will tomorrow’s workforce come from?”

The cell and gene therapy field has been advancing at a breakneck speed for the best part of a decade now, fuelled by long-awaited clinical successes, commercial breakthroughs, and a related startling increase in activity from both investors and big pharma. But with this relentless pace of growth and innovation comes the fundamental challenge of developing a sufficiently large and skilled workforce to support and maintain the sector.

In this final part, we look to the future of the cell and gene therapy workforce, exploring the motivations, skills, goals, and priorities of three individuals who are at various early stages of their careers in the sector – PhD student Tiffany Hood, recent Masters graduate Lihi Livne, and Sebastian Rudden, who is in his final year as an undergrad at University College London.